Gynecological cancers: immunotherapy and novel targeted drug appear beneficial in group of women with early-stage disease.

New studies presented at ESMO 2024 reveal that immunotherapy and a novel targeted drug show promise in treating early-stage endometrial and cervical cancers. Immunotherapy combined with standard treatments improved overall survival in high-risk locally advanced cervical cancer patients, while immunotherapy was found to be beneficial for patients with deficient mismatch repair (dMMR) tumors in high-risk endometrial cancer. Additionally, a first-in-human study found that an antibody drug conjugate (ADC) targeting the protein claudin 6 showed antitumor activity in heavily pretreated patients with ovarian and endometrial cancers. These findings offer new treatment options for gynecological cancers and highlight the need for further research to identify subgroups of patients who can benefit from immunotherapy. [Extracted from the article]